PD-L1 Biomarkers
News and reporting on PD-L1 biomarkers.
FDA Approves Regeneron, Sanofi's Libtayo With Agilent PD-L1 CDx in Frontline NSCLC
Advanced NSCLC patients must have a PD-L1 expression tumor proportion score of 50 percent, and no EGFR, ALK, or ROS1 alterations, to receive the drug.
Diaceutics, Alva10 Gathering Evidence Base for Improving PD-L1 Test Reimbursement
The companies will work with labs to improve payors' understanding of the costs of performing PD-L1 testing and the value it provides to patient care.
FDA Approves Merck's Keytruda, Agilent CDx in PD-L1-High Triple-Negative Breast Cancer
The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.
Inspirata, Flagship Bio Enter Digital Pathology Pact
The deal provides clinicians with digital access to Flagship Bio's TissueInsight via Inspirata's Dynamyx digital pathology product.
Biodesix, Addario Lung Cancer Institute Studying PIR Test Ability to Predict Immunotherapy Response
The serum-based proteomic test gauges a pre-treatment immune profile that has shown in retrospective studies to identify patients who are likely to respond well to anti-PD-1 therapy.